Evidence map›Paper›PMID 32624257›Full record

ReviewThe Journal of allergy and clinical immunology2020

Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.

Koa Hosoki, Abhijit Chakraborty, Sanjiv Sur

Open access · bronzeAbstract readReview
In one paragraph

Review in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Reshaping the Management of Allergic Rhinitis in Primary Care: Lessons from the COVID-19 Pandemic.International journal of environmental research and public health · 2022
    Review
  12. Article
  13. Article
  14. Impact of mental health on disease activity in mastocytosis during COVID-19 pandemic.Allergology international : official journal of the Japanese Society of Allergology · 2022
    Article
  15. COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2022
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Koa HosokiDepartment of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex.
Abhijit ChakrabortyDepartment of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex.
Sanjiv SurDepartment of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex. Electronic address: ssur@BCM.EDU.
Baylor College of Medicine · US

Funding

Role of Cytosolic DNA-multiprotein Interactome in Allergic Airway InflammationR01HL145477 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAZRA, TAPAS K, SUR, SANJIV · 2019 to 2022
$3.6M
NHLBI NIH HHS R01 HL145477
6 · The paper itself

Abstract

The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.

Indexed as

PandemicsAdenosine MonophosphateAge FactorsAlanineAngiotensin-Converting Enzyme 2Antiviral AgentsAsthmaBetacoronavirusClinical Laboratory TechniquesClinical Trials as TopicCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentCOVID-19 TestingDrug RepositioningHumansACE2 protein, humanAdenosine MonophosphateAlanineAngiotensin-Converting Enzyme 2Antiviral AgentsPeptidyl-Dipeptidase AReceptors, VirusremdesivirSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2allergic rhinitisasthmaCOVID-19receptor-binding domainsevere acute respiratory syndrome coronavirus 2TMPRSS2

Identifiers

PMID32624257
PMCPMC7331543
OpenAlexW3038765308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.